The technology of induced pluripotent stem (iPS) cells, which is a type of synthetic stem cell, enables us creating any cell from the human body without the need to access donated material. Likewise, CRISPR nucleases allow us installing any genetic modification into human cells to correct dieseases or model them to understand better pathology. The combination of these two technologies allows us tackling a wide range of diseases, many of them incurable, all of them with outstanding innovative potential.
In this project, you will optimize standard and new miniature variants of nucleases in human iPS cells. The project have a focus on nuclease technology implementation on healthy human cell systems, beyond conventional cancer cell lines testing. The editing validation will include an assortment of genes involved in early human development with implications for disease modelling and better understanding of fundmaental human developmental biology.
You will be hosted at the Arias labo f EMBL-VU Institute for Genome Editing Technologies. This project benefit from robust international collaboration in Europe, Japan and Taiwan. You will be supervised by Dr. Jonathan Arias (Researcher Professor), expert in genome engineering and iPS cell platforms. He will guide you to create scientific articles. Learn more about us at https://www.gmc.vu.lt/en/group-of-cell-therapeutics.
Mokslinis vadovas / supervisor: Dr. Jonathan Arias (Researcher Professor)
Kontaktai / Contacts:
tel. / phone: +370 52398245
Programme Biochemistry N 004